Obesity is a global health concern, with increasing prevalence and significant implications for morbidity and mortality. It necessitates effective management strategies for healthcare professionals to mitigate its impact on public health.
Understanding obesity as a multifactorial disease is the first step in its management. It stems from a complex interplay of genetic, environmental, and behavioral factors. Therefore, a holistic approach is necessary for effective management.
Behavioral interventions form the cornerstone of obesity management. They involve dietary modifications, increased physical activity, and behavior change strategies. These interventions can be delivered through different modalities including face-to-face interactions, group sessions, and digital platforms.
Pharmacotherapy can be considered for patients with a BMI >30 kg/m2 or >27 kg/m2 with comorbidities. The choice of medication should be individualized, considering the patient's comorbidities, potential side effects, and preferences.
For patients with severe obesity (BMI >40 kg/m2 or >35 kg/m2 with comorbidities) and those who have not achieved adequate weight loss with lifestyle interventions and pharmacotherapy, weight-loss surgery can be an option. Long-term follow-up is essential to monitor for potential complications and ensure sustained weight loss.
Effective obesity management requires a comprehensive approach encompassing behavioral interventions, pharmacotherapy, and weight-loss surgery. It is crucial for healthcare professionals to individualize the management plan, taking into account the patient's characteristics and preferences. As the prevalence of obesity continues to rise, the importance of effective management strategies cannot be overstated.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation